SEOUL, May 21 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Wednesday it expects limited impact from recent U.S. policy developments stemming from a drug pricing executive order signed by President Donald Trump. Last week, Trump announced an executive order introducing a most-favored nation (MFN) pricing model, intended to align U.S. [...]
SEOUL, May 15 (Korea Bizwire) — Celltrion Inc., a leading South Korean biopharmaceutical company, said Thursday its business will remain largely unaffected by U.S. President Donald Trump’s executive order aimed at lowering drug prices to match those in other countries. The order seeks to address a drug pricing system in which the United States pays [...]
SEOUL, May 14 (Korea Bizwire) — South Korea’s pharmaceutical and biotech companies view the Trump administration’s push to lower U.S. prescription drug prices as a potential tailwind for domestic drugmakers, particularly those in the biosimilar space. Former President Donald Trump, who is expected to run again in the 2026 election, issued an executive order last week [...]